Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
In order to design and synthesize a new class of heterocyclic analogues of natural combretastatin A-4 and its synthetic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2015
2015
BACKGROUND Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour… Expand
Is this relevant?
2014
2014
SummaryPurpose Preclinical evidence supports synergy between the vascular disrupting agent ombrabulin and various chemotherapy… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2013
2013
PURPOSE The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2007
2007
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting… Expand
Is this relevant?
Review
2004
Review
2004
  • Philip E. Thorpe
  • Clinical cancer research : an official journal of…
  • 2004
  • Corpus ID: 1739027
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2003
2003
The in vivo combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin (CDDP) was examined. The… Expand
Is this relevant?
2003
2003
A novel combretastatin A-4 derivative, AC7700, which is now in Phase I clinical trials under a new code, AVE8062, has shown… Expand
Is this relevant?
2002
2002
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1999
1999
AC-7700, a novel combretastatin A-4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?